Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Cardiovascular Conditions
Vol. 3, Issue 1, 2015
October 26, 2016 EDT
Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective
Yaariv Khaykin
,
Peter J. Mallow
,
John A. Rizzo
,
Atul Verma
,
Lauren Chun
,
Shelby Olesovsky
,
Matthew R. Reynolds
,
markov model
cost-utility
canada
atrial fibrillation
cost-effectiveness
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9837
JHEOR
1.
Khaykin Y, Mallow PJ, Rizzo JA, et al. Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective.
JHEOR
. 2016;3(1):1-12.
doi:10.36469/9837
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats